23.15 USD
-0.19 (-0.81%)
23.15 USD
0 (0%)
We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 530 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. This makes CPRX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
In the past 5 years CPRX has always been profitable.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.69%, CPRX belongs to the top of the industry, outperforming 97.17% of the companies in the same industry.
With an excellent Return On Equity value of 23.65%, CPRX belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
With an excellent Return On Invested Capital value of 21.23%, CPRX belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for CPRX is above the industry average of 18.28%.
The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
With an excellent Profit Margin value of 37.64%, CPRX belongs to the best of the industry, outperforming 96.60% of the companies in the same industry.
CPRX's Profit Margin has been stable in the last couple of years.
CPRX's Operating Margin of 44.78% is amongst the best of the industry. CPRX outperforms 99.25% of its industry peers.
In the last couple of years the Operating Margin of CPRX has grown nicely.
CPRX has a Gross Margin of 85.68%. This is amongst the best in the industry. CPRX outperforms 88.49% of its industry peers.
In the last couple of years the Gross Margin of CPRX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
The number of shares outstanding for CPRX has been increased compared to 1 year ago.
Compared to 5 years ago, CPRX has more shares outstanding
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 15.89 indicates that CPRX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 15.89, CPRX belongs to the best of the industry, outperforming 86.79% of the companies in the same industry.
There is no outstanding debt for CPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.89 |
ROIC/WACC2.41
WACC8.82%
2.3 Liquidity
CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CPRX (6.62) is better than 67.74% of its industry peers.
CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX has a Quick ratio of 6.40. This is in the better half of the industry: CPRX outperforms 66.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
CPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.76%, which is quite impressive.
CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 34.29% yearly.
Looking at the last year, CPRX shows a very strong growth in Revenue. The Revenue has grown by 25.56%.
Measured over the past years, CPRX shows a very strong growth in Revenue. The Revenue has been growing by 36.89% on average per year.
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
Based on estimates for the next years, CPRX will show a very strong growth in Earnings Per Share. The EPS will grow by 26.80% on average per year.
CPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.21% yearly.
EPS Next Y22.87%
EPS Next 2Y22.01%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 13.46 indicates a correct valuation of CPRX.
96.42% of the companies in the same industry are more expensive than CPRX, based on the Price/Earnings ratio.
CPRX is valuated rather cheaply when we compare the Price/Earnings ratio to 26.51, which is the current average of the S&P500 Index.
CPRX is valuated reasonably with a Price/Forward Earnings ratio of 11.87.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.74% of the companies listed in the same industry.
CPRX is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.46 | ||
| Fwd PE | 11.87 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 98.11% of the companies listed in the same industry.
CPRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.13 | ||
| EV/EBITDA | 7.34 |
4.3 Compensation for Growth
CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of CPRX may justify a higher PE ratio.
CPRX's earnings are expected to grow with 12.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.59
PEG (5Y)0.39
EPS Next 2Y22.01%
EPS Next 3Y12.53%
5. Dividend
5.1 Amount
CPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.15
-0.19 (-0.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners87.01%
Inst Owner Change1.44%
Ins Owners5.56%
Ins Owner Change1.93%
Market Cap2.85B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (52.01%)
Short Float %6.84%
Short Ratio6.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)0%
PT rev (3m)1.47%
EPS NQ rev (1m)6.21%
EPS NQ rev (3m)14.07%
EPS NY rev (1m)8.23%
EPS NY rev (3m)8.38%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.31%
Revenue NY rev (1m)2.82%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.46 | ||
| Fwd PE | 11.87 | ||
| P/S | 4.92 | ||
| P/FCF | 12.13 | ||
| P/OCF | 12.12 | ||
| P/B | 3.09 | ||
| P/tB | 3.59 | ||
| EV/EBITDA | 7.34 |
EPS(TTM)1.72
EY7.43%
EPS(NY)1.95
Fwd EY8.42%
FCF(TTM)1.91
FCFY8.25%
OCF(TTM)1.91
OCFY8.25%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)0.59
PEG (5Y)0.39
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.89 |
F-Score6
WACC8.82%
ROIC/WACC2.41
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y22.87%
EPS Next 2Y22.01%
EPS Next 3Y12.53%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year19.37%
Revenue Next 2Y13.12%
Revenue Next 3Y11.23%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status for CPRX stock?
ChartMill assigns a valuation rating of 8 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?
The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 22.87% in the next year.